The prestigious American College of Cardiology (ACC) did not accept a controversial study of Merck and Schering-Plough's Vytorin as a highlighted presentation at its annual meeting in March, a key showcase for data on heart drugs, but the group plans to include the presentation at its meeting in some other form.